Benchmark Starts Trillium Therapeutics (TRIL) at Buy
Tweet Send to a Friend
Benchmark initiates coverage on Trillium Therapeutics (NASDAQ: TRIL) with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
